---
title: Patient Navigation in Cancer Survivorship at a Safety Net Institution
nct_id: NCT03271099
overall_status: COMPLETED
phase: NA
sponsor: Boston Medical Center
study_type: INTERVENTIONAL
primary_condition: Cancer
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03271099.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03271099"
ct_last_update_post_date: 2021-09-08
last_seen_at: "2026-05-12T07:24:48.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Patient Navigation in Cancer Survivorship at a Safety Net Institution

**Official Title:** Patient Navigation as Part of the Cancer Survivorship Care Plan at a Safety Net Institution

**NCT ID:** [NCT03271099](https://clinicaltrials.gov/study/NCT03271099)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 39
- **Lead Sponsor:** Boston Medical Center
- **Collaborators:** Harvard Pilgrim Health Care
- **Conditions:** Cancer
- **Start Date:** 2017-10-16
- **Completion Date:** 2020-09-10
- **CT.gov Last Update:** 2021-09-08

## Brief Summary

This study seeks to enroll patients receiving a Survivorship Care Plan following curative therapy for cancer. Participants will be randomly assigned to receive usual care or to be followed by a Patient Navigator as part of their Survivorship Care Plan.

## Detailed Description

This study seeks to enroll patients receiving a Survivorship Care Plan following curative therapy for cancer. Participants will be randomly assigned to receive usual care or to be followed by a Patient Navigator as part of their Survivorship Care Plan.

Study participation for all participants will be for up to 9 months, with study visits approximately every 3 months, based on standard clinical follow-up. All participants will be administered quality of life surveys by a Clinical Research Associate at study entry, mid-study (approximately 3-6 months) and at study completion.

The following factors will be compared between arms:

* Missed/kept appointments
* Use of urgent/emergent care
* Quality of Life in relation to survivorship care
* Participants lost to care

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Stage I, II, III or IVa Cancer diagnosis (may include Solitary plasmacytoma, Diffuse Large B-Cell Lymphoma (DLBCL), ductal carcinoma in situ (DCIS) of the breast)
* Completed treatment with curative intent within the past 12 months. (May be on maintenance therapy.)

Exclusion Criteria:

* Distant Metastatic disease
* Non-curable disease
* Recurrence of disease prior to enrollment
* Require ongoing navigation from the treatment navigator
* Enrolled/active in another randomized study (Project SUPPORT)
```

## Arms

- **Usual Care** (NO_INTERVENTION) — Usual care
- **Navigator** (EXPERIMENTAL) — Patient navigator services provided as part of survivorship care plan

## Interventions

- **Navigator** (OTHER) — Patient Navigation services will be provided to try to eliminate barriers in pursuing survivorship surveillance

## Primary Outcomes

- **Missed appointments** _(time frame: 9 months)_ — The research team will document the number of cancer care appointments scheduled and of those, how many appointments were missed (obtained by medical record and by patient report in case a visit was outside of study institution).

## Secondary Outcomes

- **Urgent/emergent care** _(time frame: 9 months)_
- **Cancer Needs Distress** _(time frame: 9 months)_
- **New Survivor Survey** _(time frame: 9 months)_
- **Lost to Care** _(time frame: 9 months)_

## Locations (1)

- Boston Medical Center, Boston, Massachusetts, United States

## Recent Field Changes (last 30 days)

- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.boston medical center|boston|massachusetts|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03271099.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03271099*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*